Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Stock Information for Aravive Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aravive Inc.

Aravive, Inc. to Delist from The Nasdaq Stock Market
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
Aravive To Participate in the Jefferies Global Healthcare Conference
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.